Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > screenshot question

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon Jul 27, 2021 5:05pm

174 Views

Post# 33614047

RE:RE:screenshot question

I'm pretty sure the mention of 11 patients having received an optimised treatment is an error. It may be more like 5-6 of which we only see 2or 3 on AGM slide. IMO

CancerSlayer wrote:

DJDawg wrote: Regarding the recent AGM screenshot from recently.....

- the most recent documents talk about the 7 optimized Primary and then the 11 that go a do-over with an optimized "Maintenance" treatment. I'm assuming that for those of the 11 that were grossly underdosed before, this optimized treatment would be kind of like a first real treatment.
- if so, how do we see them in the screenshot? One would assume it would show as PR patients jumping into the CR group count. Or NR patients jumpting into the CR or PR groupings. Which we are not seeing. I personally wonder if they 11 optimized Maintenance patients are not represented on the table at all...yet.

Incidentally, I can see why they picked 6 m for the second treatment in all comers. The CR and PR group numbers holds from 90 to 180 days and then starts losing patients. So that logic is good to see.

I've seen some pharma results where they show every patient's journey individually so you can see where they are. Wish they did that here.

Hi DJDawg...Per the Sept. 24 release:

Study II has enrolled and treated 12 patients to date. Out of the 7 patients that are eligible to receive the second treatment, 5 have been treated and 2 are pending. 2 out of the last 5 patients treated for the second time have been treated with the optimized Study II treatment, which will also be the case for the 2 patients that are pending their second treatment.

Efficacy to date at the 90 day assessment includes:

3 out of 12 patients (25%) have demonstrated a Complete Response (“CR”) (Negative cystoscopy and negative (including atypical) urine cytology

3 out of 12 patients (25%) have demonstrated a Partial Response (“PR”) (2 patients with negative cystoscopy and positive urine cytology and 1 patient with positive cystoscopy and negative urine cytology), with 2 of these patients having received second treatment.

There are a total of 23 patients noted in that screen shot, which would include all patients to that point, optimized & not... The reason we may not have seen a big jump after the optimized maintenance treatment could be due to the possibility that only 1 of the 3 PRs from the first 12 patients actually received the optimized maintenance treatment. It doesn't specify above (blue highlight) whether the 2 PRs who received their 2nd treatment was optimized or not. If you recall, 3 of the first 12 had already received a 2nd/maintenance treatment prior to the treatment protocol being optimized.